Privia Health Group (PRVA) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Privia Health Group (NASDAQ: PRVA) recently:

• 1/9/2026 – Privia Health Group is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $31.00 price target on the stock.
• 1/6/2026 – Privia Health Group was given a new $31.00 price target on by analysts at Wolfe Research.
• 1/6/2026 – Privia Health Group had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/29/2025 – Privia Health Group had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Privia Health Group had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Privia Health Group had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Privia Health Group had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/4/2025 – Privia Health Group had its “overweight” rating reaffirmed by analysts at Stephens. They now have a $32.00 price target on the stock.
• 12/1/2025 – Privia Health Group had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Privia Health Group had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Privia Health Group had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Privia Health Group had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Privia Health Group had its price target raised by analysts at JPMorgan Chase & Co. from $32.00 to $33.00. They now have an “overweight” rating on the stock.
• 11/13/2025 – Privia Health Group is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $30.00 price target on the stock.
• 11/12/2025 – Privia Health Group had its price target raised by analysts at Canaccord Genuity Group Inc. from $32.00 to $34.00. They now have a “buy” rating on the stock.
• 11/10/2025 – Privia Health Group had its price target raised by analysts at Barclays PLC from $22.00 to $23.00. They now have an “equal weight” rating on the stock.
• 11/10/2025 – Privia Health Group had its “buy” rating reaffirmed by analysts at Truist Financial Corporation. They now have a $31.00 price target on the stock, up previously from $30.00.

Insider Buying and Selling

In related news, Director Matthew Shawn Morris sold 13,647 shares of the firm’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $25.01, for a total transaction of $341,311.47. Following the completion of the transaction, the director owned 68,188 shares of the company’s stock, valued at $1,705,381.88. This trade represents a 16.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO David Mountcastle sold 23,887 shares of the company’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $25.03, for a total transaction of $597,891.61. Following the completion of the sale, the chief financial officer directly owned 172,909 shares in the company, valued at approximately $4,327,912.27. The trade was a 12.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 10.70% of the stock is owned by corporate insiders.

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.